Oxaliplatin (L.OHP): a new reality in colorectal cancer
1998

Oxaliplatin: A New Treatment for Colorectal Cancer

Sample size: 122 publication Evidence: moderate

Author Information

Author(s): H Bleiberg

Primary Institution: Institut Jules Bordet, Brussels, Belgium

Hypothesis

Oxaliplatin is effective in treating advanced colorectal cancer.

Conclusion

Oxaliplatin is active and well tolerated in treating metastatic colorectal cancer, both alone and in combination with 5-FU/folinic acid.

Supporting Evidence

  • Oxaliplatin has shown a 27% overall response rate in previously untreated patients.
  • Patients receiving oxaliplatin in combination with 5-FU/FA had a response rate three times higher than those receiving 5-FU/FA alone.
  • Median survival for patients treated with oxaliplatin was over 12 months.

Takeaway

Oxaliplatin is a new medicine that helps people with a type of cancer called colorectal cancer, and it works well with fewer side effects.

Methodology

The study involved multiple phase II trials assessing oxaliplatin's effectiveness and safety in patients with metastatic colorectal cancer.

Limitations

The study primarily focused on specific patient populations and may not represent all colorectal cancer patients.

Participant Demographics

Patients included those with previously untreated and 5-FU resistant metastatic colorectal cancer, with a median age of 67 years.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 0.03-0.19

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication